The U.S. Food and Drug Administration has approved Pasatru for adults with fibrodysplasia ossificans progressiva, giving Regeneron Pharmaceuticals (REGN) another rare disease therapy that investors can now factor into the companys product mix.
Regeneron Pharmaceuticals' share price has climbed 33.1% over the past 90 days and 8.0% over the past month, while the 1-year total shareholder return of 43.3% points to strong recent gains as investors weigh the Pasatru approval alongside the ongoing Libtayo recall.
Spot 19 high quality undiscovered gems that, similar to Regeneron Pharmaceuticals after its Pasatru approval, are quietly building rare disease or specialty drug portfolios that the wider market may not be pricing in yet.After a 33.1% move in 90 days, Regeneron Pharmaceuticals now trades within sight of published price targets, yet Pasatru and the broader pipeline reshape the story. Has the stock already done the hard work, or is meaningful upside still ahead?
Most Popular Narrative: 1.1% Undervalued
Regeneron Pharmaceuticals last closed at $823.82 versus a widely followed fair value narrative of $833.31, which ties recent Pasatru momentum to longer term cash flow power and pipeline expectations.
Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.
Want to see what underpins that projected cash flow engine? The narrative leans on specific revenue growth, margin expansion and a higher future earnings multiple that the current share price does not fully mirror.
Result: Fair Value of $833.31 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Regeneron Pharmaceuticals still faces key risks, including EYLEA competition that could pressure revenue and trial setbacks such as fianlimab, which may weaken confidence in the pipeline.
Find out about the key risks to this Regeneron Pharmaceuticals narrative.
Next Steps
With sentiment around Regeneron Pharmaceuticals leaning positive, it makes sense to pressure test the story using your own tools and timing. To see what current optimism is based on, review the 2 key rewards
Looking for more investment ideas beyond Regeneron Pharmaceuticals?
If you like the setup around Regeneron Pharmaceuticals, do not stop here. Use the Simply Wall Street screener to explore other ideas before the crowd catches on.
- Target reliable income streams by reviewing a focused list of potential yield opportunities through the 12 dividend fortresses.
- Identify quality at a sensible price by scanning the 50 high quality undervalued stocks that might fit your return and risk preferences.
- Find companies that may help cushion portfolio swings by checking out the 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com